Skip to main content

Azitra, Inc.

corporate_fare Company Profile

Azitra, Inc.

AZTR·NYSE·Life Sciences·CIK 0001701478

Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company was formed as a Delaware corporation on January 2, 2014, and has not commenced commercial operations. Azitra has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains. Azitra's initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which it considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. The particular species demonstrates a number of well-described properties in the skin. As of the date of the report, Azitra has identified, among its microbial library, over 60 distinct bacterial species that it believes are capable of being engineered to create living organisms or engineered proteins with significant therapeutic effect. Azitra describes itself as a pioneer in genetically engineering bacteria for therapeutic use in dermatology.

Azitra, Inc. (NYSE:AZTR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for AZTR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 2 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for AZTR spans SCHEDULE 13D, 10-Q.

Recent high-impact activity:

  • Young Pharmaceuticals Discloses 5.22% Azitra Stake, Plans Board Engagement
  • Azitra Q3 10-Q: Going-Concern Doubt, $3.75M Cash, Equity Below NYSE American Minimum

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$10.96M
Diluted EPS
-$2.25
Op. Cash Flow
-$11.22M
Free Cash Flow
-$11.25M
Operating Income
-$10.97M
Cash & Equivalents
$2.07M
Debt / Equity
0.00×
Shares Outstanding
10.74M sh
Source: 10-K · filed 2026-02-27 · accession 0001701478-26-000013

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 305,802 shares in AZTR as of the October 30, 2026 settlement, a 172.3% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 16, 2026, 82.9% of AZTR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)305,802 shares as of October 30, 2026
Change vs prior period▲ 172.3%
Days to cover1.00 at avg daily volume of 14,623,589
Daily short volume (FINRA facilities)82.9% of 117,861 shares on November 16, 2026
5-day average short volume58.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$0.5805 -7.42% today
52-week range · as of 2026-11-16 $0.518 – $5
Market cap
$3.8M
Volume
162.3K (0.0× avg)
3-mo avg 5.5M
Live data · 2026-11-17 01:37 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed AZTR - Latest Insights

AZTR
Nov 16, 2026, 5:15 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $0.630
Real-time Price: $0.5805 info
Change: -$0.0495 (-8%) info
Market Cap: $3.8M info
AZTR
Nov 12, 2026, 4:13 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.7224
Real-time Price: $0.5805 info
Change: -$0.1419 (-20%) info
Market Cap: $3.8M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets